MARKET

NYMX

NYMX

Nymox
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.350
-0.030
-1.26%
Closed 16:00 10/22 EDT
OPEN
2.400
PREV CLOSE
2.380
HIGH
2.400
LOW
2.290
VOLUME
82.97K
TURNOVER
--
52 WEEK HIGH
4.790
52 WEEK LOW
1.660
MARKET CAP
179.35M
P/E (TTM)
-15.5526
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Nymox Pharmaceutical to raise $9M in direct stock offering
Nymox Pharmaceutical ([[NYMX]] -10.6%) announces direct offering of $9M shares of its common stock priced at $2.50/share; proceeds will be used for general corporate purposes.Offer is expected to close on Aug.
Seekingalpha · 08/12 13:32
Nymox Pharmaceutical to raise $9M in direct stock offering
Nymox Pharmaceutical ([[NYMX]] -10.6%) announces direct offering of $9M shares of its common stock priced at $2.50/share; proceeds will be used for general corporate purposes.Offer is expected to close on Aug.
Seekingalpha · 08/12 13:32
Nymox 6-K Filing Shows $9M Registered Direct Offering
Benzinga · 08/12 13:13
Nymox Pharma Offers Update On Current Developments
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report current updates on the Company's most important ongoing developments. The Company reports further significant and important progress has been made
Benzinga · 07/28 13:34
NYMOX Provides Current Update on Key Company Developments
HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing developments. The Company reports further significant and important progress
GlobeNewswire · 07/28 13:30
Nymox Pharmaceutical Entered Into Sales Agreement With Alliance Global Partners As Sales Agent
Benzinga · 07/20 20:25
Nymox (+8%) on track to file fexapotide applications in ~four months
Seeking Alpha - Article · 06/19 15:54
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
GlobeNewswire · 06/19 14:30
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NYMX. Analyze the recent business situations of Nymox through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 78
Institutional Holdings: 5.19M
% Owned: 6.79%
Shares Outstanding: 76.32M
TypeInstitutionsShares
Increased
12
2.17M
New
31
1.26M
Decreased
11
541.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.08%
Pharmaceuticals & Medical Research
+0.24%
Key Executives
Chairman/Chief Executive Officer/President/Director
Paul Averback
Chief Financial Officer
Erik Danielsen
General Counsel/Independent Director/Director
Randall Lanham
Director/Independent Director
Richard Cutler
Independent Director
David Morse
Director/Independent Director
James Robinson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NYMX
Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Nymox Pharmaceutical Corp stock information, including NASDAQ:NYMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NYMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NYMX stock methods without spending real money on the virtual paper trading platform.